Allogene Therapeutics, Inc. – NASDAQ:ALLO

Add to watchlist

$1.07

-1.11

-51.14%

Market closed

Open in about 17 hours

-20.65%

month

-20.65%

quarter

-31.56%

year

Market Cap	392.08M
Enterprise value	703.51M

P/E	-2.09
EV/Sales	3589.34
EV/EBITDA	-3.13
Price/Sales	3419.86
Price/Book	1.00
PEG ratio	0.09
EPS	-1.79

Revenue	130K
EBITDA	-270.67M
Income	-290.08M
Revenue Q/Q	-57.69%
Revenue Y/Y	-44.44%

Profit margin	-121318.88%
Oper. margin	-121977.04%
Gross margin	0%
EBIT margin	-121977.04%
EBITDA margin	-208214.62%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Profit margin
Jun 2023	44K	-77.98M	-177247.73%
Sep 2023	43K	-61.31M	-142593.02%
Dec 2023	21K	-85.77M	-408466.67%
Mar 2024	22K	-65M	-295454.55%

Allogene Therapeutics Financials Estimate

Q Y

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Analyst Estimates
Mar 2024	22K	-65M	-295454.55%
Sep 2025	11.5K	-63.77M	-554600.68%
Oct 2025	10.63K	-64.53M	-606801.27%
Dec 2025	10.63K	-65.38M	-614736.11%

Analysts Price target
Financials & Ratios estimates

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Debt to assets
Jun 2023	770971000	148.06M	19.21%
Sep 2023	712326000	129.22M	18.14%
Dec 2023	642837000	130.60M	20.32%
Mar 2024	586350000	124.98M	21.32%

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Cash Flow
Jun 2023	-61.85M	17.16M	89.52M
Sep 2023	-55.53M	-34.26M	4.28M
Dec 2023	-53.70M	67.46M	155K
Mar 2024	-55.89M	22.13M	1.65M

Allogene Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Allogene Therapeutics
Employees

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Employee count
Sep 2023	359
Oct 2023	359
Nov 2023	359
Dec 2023	359
Jan 2024	359
Feb 2024	359
Apr 2024	232
May 2024	232
Jun 2024	232
Jul 2024	232

Allogene Therapeutics
Hedge Funds Holdings Q1 2023

23.55% -53.70%

of ALLO is owned by hedge funds

102 -60

hedge funds hold ALLO stock

33.70M -77.27M

shares is hold by hedge funds

ALLO hedge funds holdings changes

Allogene Therapeutics
Insider Trading

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	190	0
May 2024	1724137	11200
Jun 2024	0	18641
Dec 2024	0	18357

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	9 Dec 2024	MESSEMER DEBORAH M. director director	Common Stock	9,136	$2.18	$19,916
Sale	5 Dec 2024	HUMER FRANZ B director director	Common Stock	9,221	$2.16	$19,917
Sale	18 Jun 2024	MESSEMER DEBORAH M. director director	Common Stock	18,641	$2.28	$42,483
Sale	30 May 2024	HUMER FRANZ B director director	Common Stock	11,200	$2.34	$26,186
Purchase	16 May 2024	BELLDEGRUN ARIE director director	Common Stock	1,724,137	$2.9	$4,999,997
Purchase	30 Jan 2024	PARKER GEOFFREY M. officer: CHIEF FI..	Common Stock	190	$3.6	$683
Sale	18 Dec 2023	MESSEMER DEBORAH M. director director	Common Stock	18,640	$2.7	$50,309
Sale	7 Aug 2023	MAYO STEPHEN director director	Common Stock	10,000	$4.29	$42,860
Sale	13 Feb 2023	BHAVNAGRI VEER officer: General ..	Common Stock	3,000	$6.85	$20,550
Sale	17 Jan 2023	BHAVNAGRI VEER officer: General ..	Common Stock	3,000	$7.04	$21,120

ALLO insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH Filling date: 4 Mar 2022 Issue date: 8 Sep 2022	4 Mar 2022	8 Sep 2022
Application	Application KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS Filling date: 28 Jan 2022 Issue date: 11 Aug 2022	28 Jan 2022	11 Aug 2022
Application	Application FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTS Filling date: 3 Feb 2022 Issue date: 4 Aug 2022	3 Feb 2022	4 Aug 2022
Application	Application MODIFIED CASPASE-9 POLYPEPTIDES AND METHODS OF USE THEREOF Filling date: 8 Apr 2022 Issue date: 28 Jul 2022	8 Apr 2022	28 Jul 2022
Application	Application PROTEASE-ACTIVATING CD45-GATE CAR Filling date: 21 Dec 2021 Issue date: 21 Jul 2022	21 Dec 2021	21 Jul 2022
Application	Application METHODS AND REAGENTS FOR CHARACTERIZING CAR T CELLS FOR THERAPIES Filling date: 14 Dec 2021 Issue date: 16 Jun 2022	14 Dec 2021	16 Jun 2022
Grant	Grant Utility: Modified caspase-9 polypeptides and methods of use thereof Filling date: 31 Oct 2018 Issue date: 10 May 2022	31 Oct 2018	10 May 2022
Application	Application INHIBITORY CHIMERIC ANTIGEN RECEPTORS Filling date: 26 Jul 2021 Issue date: 3 Feb 2022	26 Jul 2021	3 Feb 2022
Application	Application CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED SIGNALING AND ACTIVITIES AND USES THEREOF Filling date: 21 Jul 2021 Issue date: 27 Jan 2022	21 Jul 2021	27 Jan 2022
Application	Application BCMA CAR-T CELLS WITH ENHANCED ACTIVITIES Filling date: 24 Feb 2021 Issue date: 26 Aug 2021	24 Feb 2021	26 Aug 2021

Allogene Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 13 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 14 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

ALLO earnings call transcripts

Allogene Therapeutics
Executives

Insider	Age	Compensation
Dr. David D. Chang M.D., Ph.D. (1960) Co-Founder, Pres, Chief Executive Officer & Director	65	$1,260,000
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. (1949) Co-Founder & Executive Chairman	76	$845,190
Dr. Rafael G. Amado (1964) Chief Medical Officer and Executive Vice President of R&D	61	$840,000
Dr. Eric Thomas Schmidt Ph.D. (1970) Chief Financial Officer	55	$660,000
Dr. Alison Moore Ph.D. (1967) Chief Technical Officer	58	$660,000
Mr. Veer Bhavnagri (1983) Gen. Counsel & Compliance Officer	42	$646,880
Mr. Joshua A. Kazam (1977) Co-Founder & Director	48	$390,000

Allogene Therapeutics
Latest News

Monday, 16 December 2024
08:30	Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Thursday, 12 December 2024
08:30	Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman	globenewswire.com
Monday, 2 December 2024
14:20	Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?	zacks.com
Monday, 25 November 2024
13:01	Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why	zacks.com
Tuesday, 19 November 2024
08:30	Allogene Therapeutics Announces Participation in December Investor Conferences	globenewswire.com
Monday, 18 November 2024
08:30	Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence	globenewswire.com
Friday, 8 November 2024
11:15	Allogene's Q3 Loss Narrower Than Expected, Sales Nil	zacks.com
Thursday, 7 November 2024
20:59	Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:02	Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update	globenewswire.com
10:00	Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS	globenewswire.com
Tuesday, 5 November 2024
09:10	Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting	globenewswire.com
Thursday, 31 October 2024
11:06	Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know	zacks.com
Wednesday, 30 October 2024
08:30	Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update	globenewswire.com
Wednesday, 2 October 2024
16:11	Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity	gurufocus.com
Monday, 30 September 2024
11:47	Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement	seekingalpha.com
08:30	Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference	globenewswire.com
Tuesday, 24 September 2024
15:00	ALLO Communications Lays Foundation for Groundbreaking Business and Residential Experiences Over 50G PON Delivered With the Calix Broadband Platform	businesswire.com
Monday, 16 September 2024
08:00	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma	prnewswire.com
Saturday, 7 September 2024
07:55	3 Hot Penny Stocks to Buy With $1000	247wallst.com
Friday, 6 September 2024
12:37	Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?	zacks.com
Monday, 26 August 2024
23:39	Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies	seekingalpha.com
Saturday, 10 August 2024
00:34	Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
10:51	Allogene (ALLO) Posts Narrower Than Expected Loss in Q2	zacks.com
08:30	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	globenewswire.com
06:00	7 Biotech Stocks to Buy for Their Game-Changing Potential	investorplace.com
Wednesday, 7 August 2024
16:02	Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update	globenewswire.com
Wednesday, 31 July 2024
08:30	Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update	globenewswire.com
Monday, 1 July 2024
08:30	Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)	globenewswire.com
Thursday, 20 June 2024
08:30	Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse	globenewswire.com
Wednesday, 12 June 2024
13:09	Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products	seekingalpha.com

Ideas & Opinions

Seeking Alpha 14 Aug 2025

Allogene Therapeutics: Important Catalysts Guided For Early 2026
Seeking Alpha 29 May 2025

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
Seeking Alpha 28 May 2025

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
Seeking Alpha 12 Dec 2024

Cellectis: Poised To Start Answering Questions In 2025
Seeking Alpha 12 Jun 2024

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Seeking Alpha 30 May 2024

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
Seeking Alpha 5 Apr 2024

Showcasing Seeking Alpha's March 2024 New Analysts
Seeking Alpha 2 Sep 2023

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch
Seeking Alpha 26 Jul 2023

Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before
Seeking Alpha 12 Jul 2023

SpringWorks Therapeutics: FDA Decision Date Ahead

Frequently Asked Questions (FAQ)

What's the price of Allogene Therapeutics stock today?

One share of Allogene Therapeutics stock can currently be purchased for approximately $1.07.
When is Allogene Therapeutics's next earnings date?

Unfortunately, Allogene Therapeutics's (ALLO) next earnings date is currently unknown.
Does Allogene Therapeutics pay dividends?

No, Allogene Therapeutics does not pay dividends.
How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of 392.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.91% to 95K US dollars.
What is Allogene Therapeutics's stock symbol?

Allogene Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALLO".
What is Allogene Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Allogene Therapeutics?

Shares of Allogene Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Allogene Therapeutics's key executives?
Allogene Therapeutics's management team includes the following people:
- Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,260,000)
- Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Executive Chairman(age: 76, pay: $845,190)
- Dr. Rafael G. Amado Chief Medical Officer and Executive Vice President of R&D(age: 61, pay: $840,000)
- Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer(age: 55, pay: $660,000)
- Dr. Alison Moore Ph.D. Chief Technical Officer(age: 58, pay: $660,000)
- Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer(age: 42, pay: $646,880)
- Mr. Joshua A. Kazam Co-Founder & Director(age: 48, pay: $390,000)
Is Allogene Therapeutics founder-led company?

Yes, Allogene Therapeutics is a company led by its founders Dr. David D. Chang M.D., Ph.D., Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. and Mr. Joshua A. Kazam.
How many employees does Allogene Therapeutics have?

As Jul 2024, Allogene Therapeutics employs 232 workers.
When Allogene Therapeutics went public?

Allogene Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 11 Oct 2018.
What is Allogene Therapeutics's official website?

The official website for Allogene Therapeutics is allogene.com.
Where are Allogene Therapeutics's headquarters?

Allogene Therapeutics is headquartered at 210 East Grand Avenue, South San Francisco, CA.
How can i contact Allogene Therapeutics?

Allogene Therapeutics's mailing address is 210 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 04572700.

Allogene Therapeutics, Inc.

allogene.com

Exchange:

NASDAQ

Full time employees:

232

Industry:

Biotechnology

Sector:

Healthcare

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

+65 04572700

210 East Grand Avenue
South San Francisco, CA 94080

CIK: 0001737287
ISIN: US0197701065
CUSIP: 019770106